STAT3 and infection: Although the definitive treatment for STAT-related disorders is currently represented by HSCT, the use of JAK inhibitors has demonstrated promising responses in the management of autoimmunity, infections, and lymphoproliferation in STAT1 GOF and STAT3 GOF [85].